Key Stats for Eli Lilly Stock
- Price change for Eli Lilly stock in last 6 months: 23%
- $LLY Stock Price as of Oct. 2: $1143
- 52-Week High: $1293
- $LLY Stock Price Target: $1329
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Eli Lilly (LLY) shared early results for a new type of obesity treatment this week. The drug is eloralintide.
It targets the amylin pathway, which helps control hunger and fullness. It works differently from GLP-1 drugs like tirzepatide, the ingredient in Zepbound and Mounjaro.
In a Phase 2 trial, patients had obesity and Type 2 diabetes. At 48 weeks, those on the highest-dose combo lost an average of 23.3% of their body weight. Patients on a high dose of tirzepatide lost 14.8%.
Lilly is developing eloralintide on its own and as a combo with tirzepatide. Leerink analyst David Risinger expects the standalone drug to launch in 2029 and the combo in 2030.
He forecasts $23.2 billion in annual sales by the end of 2035. He also said over 10 million people may not respond well to GLP-1s.
There are some concerns. The study was small.
More patients on the combo stopped treatment because of side effects, between 10.8% and 27%, compared with 2.9% on tirzepatide alone. Dr. Caroline Apovian said, “27% is not a good number.”
Phase 3 trials start later this year.
Lilly is not alone. Novo is pushing its own amylin-based drugs, including CagriSema, which is expected to launch early next year.
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free) >>>
What the Market Is Telling Us About Eli Lilly Stock
This news gives Eli Lilly stock a longer-term story. Amylin could become a second growth engine next to its GLP-1 drugs.
But the launch is years away, so it won’t drive Eli Lilly stock in the near term.
Today’s business is already strong. Q2 revenue grew 48%. Zepbound and Mounjaro brought in $14.9 billion.
Lilly raised its 2026 revenue guidance to $85 billion to $87 billion. It also raised earnings-per-share guidance to $35.50 to $36.50.
Lilly also has other obesity drugs moving forward.
It plans to submit retatrutide in the U.S. in Q1 2027. Its oral drug, Foundayo, is under review in more than 40 countries.
Competition and side effects remain key risks. Eli Lilly stock may continue to react to Phase 3 results and how Novo’s rival drugs perform.
Estimate a company’s fair value instantly (Free with TIKR) >>>
So what is Eli Lilly stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what LLY stock could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
